3.23.2 html 350 404 1 false 107 0 false 8 false false R1.htm 100000 - Document - Cover Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DocumentCover Cover Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100030 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100050 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLossUnaudited Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 100060 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitUnaudited Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 6 false false R7.htm 100070 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 10 false false R11.htm 995465 - Disclosure - Liquidity and Going Concern Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureLiquidityAndGoingConcern Liquidity and Going Concern Notes 11 false false R12.htm 995475 - Disclosure - Fair Value Measurements Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 995485 - Disclosure - Investments Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureInvestments Investments Notes 13 false false R14.htm 995495 - Disclosure - Goodwill and Intangible Assets Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 995505 - Disclosure - Significant Agreements and Contracts Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureSignificantAgreementsAndContracts Significant Agreements and Contracts Notes 15 false false R16.htm 995515 - Disclosure - Debt Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureDebt Debt Notes 16 false false R17.htm 995525 - Disclosure - Stockholders' Equity Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 995535 - Disclosure - Stock-Based Compensation Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 995545 - Disclosure - Commitments and Contingencies Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 995555 - Disclosure - Income Taxes Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 995565 - Disclosure - Net Loss Per Share Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 21 false false R22.htm 995575 - Disclosure - Segment Information Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureSegmentInformation Segment Information Notes 22 false false R23.htm 995585 - Disclosure - Liabilities Subject to Compromise Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureLiabilitiesSubjectToCompromise Liabilities Subject to Compromise Notes 23 false false R24.htm 995595 - Disclosure - Reorganization Items, Net Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureReorganizationItemsNet Reorganization Items, Net Notes 24 false false R25.htm 995605 - Disclosure - Condensed Combined Debtor-In-Possession Financial Information Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformation1 Condensed Combined Debtor-In-Possession Financial Information Notes 25 false false R26.htm 995615 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 26 false false R27.htm 995625 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 27 false false R28.htm 995635 - Disclosure - Fair Value Measurements (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements 28 false false R29.htm 995645 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets 29 false false R30.htm 995655 - Disclosure - Debt (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureDebtTables Debt (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureDebt 30 false false R31.htm 995665 - Disclosure - Stock-Based Compensation (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensation 31 false false R32.htm 995675 - Disclosure - Commitments and Contingencies (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 32 false false R33.htm 995685 - Disclosure - Net Loss Per Share (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureNetLossPerShare 33 false false R34.htm 995695 - Disclosure - Segment Information (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureSegmentInformationTables Segment Information (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureSegmentInformation 34 false false R35.htm 995705 - Disclosure - Liabilities Subject to Compromise (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureLiabilitiesSubjectToCompromiseTables Liabilities Subject to Compromise (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureLiabilitiesSubjectToCompromise 35 false false R36.htm 995715 - Disclosure - Reorganization Items (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureReorganizationItemsTables Reorganization Items (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureReorganizationItemsNet 36 false false R37.htm 995725 - Disclosure - Condensed Combined Debtor-In-Possession Financial Information (Tables) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformationTables Condensed Combined Debtor-In-Possession Financial Information (Tables) Tables http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformation1 37 false false R38.htm 995735 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Product and Service Type (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDisaggregatedByProductAndServiceTypeDetails Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Product and Service Type (Details) Details 38 false false R39.htm 995745 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Details 39 false false R40.htm 995755 - Disclosure - Liquidity and Going Concern - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails Liquidity and Going Concern - Additional Information (Details) Details 40 false false R41.htm 995765 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 41 false false R42.htm 995775 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 42 false false R43.htm 995785 - Disclosure - Fair Value Measurements - Summary of Inputs used in Valuing Convertible Debentures (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfInputsUsedInValuingConvertibleDebenturesDetails Fair Value Measurements - Summary of Inputs used in Valuing Convertible Debentures (Details) Details 43 false false R44.htm 995795 - Disclosure - Fair Value Measurements - Summary of Derivative Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details Fair Value Measurements - Summary of Derivative Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) Details 44 false false R45.htm 995805 - Disclosure - Investment - Celularity - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureInvestmentCelularityAdditionalInformationDetails Investment - Celularity - Additional Information (Details) Details 45 false false R46.htm 995815 - Disclosure - Investments - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails Investments - Additional Information (Details) Details 46 false false R47.htm 995825 - Disclosure - Investments - NANTibody - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails Investments - NANTibody - Additional Information (Details) Details 47 false false R48.htm 995835 - Disclosure - Investments - NantStem - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails Investments - NantStem - Additional Information (Details) Details 48 false false R49.htm 995845 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails Goodwill and Intangible Assets - Additional Information (Details) Details 49 false false R50.htm 995855 - Disclosure - Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Details) Details 50 false false R51.htm 995865 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Details) Details 51 false false R52.htm 995875 - Disclosure - Significant Agreements and Contracts - Zhengzhou Fortune Bioscience Co., Ltd. - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureSignificantAgreementsAndContractsZhengzhouFortuneBioscienceCoLtdAdditionalInformationDetails Significant Agreements and Contracts - Zhengzhou Fortune Bioscience Co., Ltd. - Additional Information (Details) Details 52 false false R53.htm 995885 - Disclosure - Debt - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureDebtAdditionalInformationDetails Debt - Additional Information (Details) Details 53 false false R54.htm 995895 - Disclosure - Debt - Schedule of Borrowings under ACEA Significant Debt Arrangements (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureDebtScheduleOfBorrowingsUnderAceaSignificantDebtArrangementsDetails Debt - Schedule of Borrowings under ACEA Significant Debt Arrangements (Details) Details 54 false false R55.htm 995905 - Disclosure - Debt - Schedule of Future Repayments under the Contract (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureDebtScheduleOfFutureRepaymentsUnderTheContractDetails Debt - Schedule of Future Repayments under the Contract (Details) Details 55 false false R56.htm 995915 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 56 false false R57.htm 995925 - Disclosure - Stock-Based Compensation - 2019 Stock Incentive Plan - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensation2019StockIncentivePlanAdditionalInformationDetails Stock-Based Compensation - 2019 Stock Incentive Plan - Additional Information (Details) Details 57 false false R58.htm 995935 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 58 false false R59.htm 995945 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit ("RSU") Activity (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetails Stock-Based Compensation - Summary of Restricted Stock Unit ("RSU") Activity (Details) Details 59 false false R60.htm 995955 - Disclosure - Stock-Based Compensation - Scilex Holding Company - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensationScilexHoldingCompanyAdditionalInformationDetails Stock-Based Compensation - Scilex Holding Company - Additional Information (Details) Details 60 false false R61.htm 995965 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetails Stock-Based Compensation - Employee Stock Purchase Plan - Additional Information (Details) Details 61 false false R62.htm 995975 - Disclosure - Stock-Based Compensation - CEO Performance Award - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureStockbasedCompensationCeoPerformanceAwardAdditionalInformationDetails Stock-Based Compensation - CEO Performance Award - Additional Information (Details) Details 62 false false R63.htm 995985 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 63 false false R64.htm 995995 - Disclosure - Commitments and Contingencies - Supplemental Quantitative Information Related to Leases (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSupplementalQuantitativeInformationRelatedToLeasesDetails Commitments and Contingencies - Supplemental Quantitative Information Related to Leases (Details) Details 64 false false R65.htm 996005 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liability Maturities (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails Commitments and Contingencies - Schedule of Operating Lease Liability Maturities (Details) Details 65 false false R66.htm 996015 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 66 false false R67.htm 996025 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Loss Per Share (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureNetLossPerShareReconciliationOfBasicAndDilutedLossPerShareDetails Net Loss Per Share - Reconciliation of Basic and Diluted Loss Per Share (Details) Details 67 false false R68.htm 996035 - Disclosure - Net Loss Per Share - Components of Outstanding Securities (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureNetLossPerShareComponentsOfOutstandingSecuritiesDetails Net Loss Per Share - Components of Outstanding Securities (Details) Details 68 false false R69.htm 996045 - Disclosure - Segment Information - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails Segment Information - Additional Information (Details) Details 69 false false R70.htm 996055 - Disclosure - Segment Information - Summary of Information by Reportable Segments (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails Segment Information - Summary of Information by Reportable Segments (Details) Details 70 false false R71.htm 996065 - Disclosure - Liabilities Subject to Compromise - Schedule of liability subject to compromise (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureLiabilitiesSubjectToCompromiseScheduleOfLiabilitySubjectToCompromiseDetails Liabilities Subject to Compromise - Schedule of liability subject to compromise (Details) Details 71 false false R72.htm 996075 - Disclosure - Reorganization Items, Net - Schedule of reorganization items incurred as a result of the chapter 11 (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureReorganizationItemsNetScheduleOfReorganizationItemsIncurredAsAResultOfTheChapter11Details Reorganization Items, Net - Schedule of reorganization items incurred as a result of the chapter 11 (Details) Details 72 false false R73.htm 996085 - Disclosure - Condensed Combined Debtor-In-Possession Financial Information - Schedule of Condensed Balance Sheets of Debtors (Unaudited) (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformationScheduleOfCondensedBalanceSheetsOfDebtorsUnauditedDetails Condensed Combined Debtor-In-Possession Financial Information - Schedule of Condensed Balance Sheets of Debtors (Unaudited) (Details) Details 73 false false R74.htm 996095 - Disclosure - Condensed Combined Debtor-In-Possession Financial Information - Additional Information (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformationAdditionalInformationDetails Condensed Combined Debtor-In-Possession Financial Information - Additional Information (Details) Details 74 false false R75.htm 996105 - Disclosure - Condensed Combined Debtor-In-Possession Financial Information - Schedule of Condensed Consolidated Statement of Operations of Debtors (Unaudited) (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformationScheduleOfCondensedConsolidatedStatementOfOperationsOfDebtorsUnauditedDetails Condensed Combined Debtor-In-Possession Financial Information - Schedule of Condensed Consolidated Statement of Operations of Debtors (Unaudited) (Details) Details 75 false false R76.htm 996115 - Disclosure - Condensed Combined Debtor-In-Possession Financial Information - Schedule of Condensed Consolidated Statement of Cash Flows (Unaudited) (Details) Sheet http://sorrentotherapeutics.com/20230630/taxonomy/role/DisclosureCondensedCombinedDebtorinpossessionFinancialInformationScheduleOfCondensedConsolidatedStatementOfCashFlowsUnauditedDetails Condensed Combined Debtor-In-Possession Financial Information - Schedule of Condensed Consolidated Statement of Cash Flows (Unaudited) (Details) Details 76 false false All Reports Book All Reports [dqc-0084-Durational-Aggregation] Sum of the cumulative periods of -263162000.000000 for ProfitLoss does not match the reported total of -263063000.000000, a difference of 99000.000000. Period values are: 2023-01-01/2023-03-31 -154626000, 2023-04-01/2023-06-30 -108536000. This rule takes into account possible rounding of values across periods and the decimals associated with each fact. This rule used a tolerance of 3 which is calculated by taking the lowest decimal value used in the calculation of -3. If there is a difference between the sum of the periods and the aggregate value reported the difference may be due to incorrect decimals associated with the individual fact values. The filer should check that the fact values do not have a decimal value that implies a higher level of accuracy than intended. In those rare cases where there are small immaterial differences that are less than 1% of the total and decimals are zero the rule can be overidden. This is performed by creating an extension element called ImmaterialDifferenceFlag. If this element has any value in any context in the instance then the immaterial difference will not result in an error. The rule excludes elements in the base taxonomy that cannot be aggregated such as an average, maximum or minimum value. The properties of this ProfitLoss fact are: Context: C_961bf81d-9a9a-456f-bcc2-e708de71385d, Unit: U_USD. srne-20230630.htm 1595, 2133, 2406 [dqc-0084-Durational-Aggregation] Sum of the cumulative periods of -189000.000000 for OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax does not match the reported total of 837000.000000, a difference of 1026000.000000. Period values are: 2022-01-01/2022-03-31 -1249000, 2022-04-01/2022-06-30 1060000. This rule takes into account possible rounding of values across periods and the decimals associated with each fact. This rule used a tolerance of 3 which is calculated by taking the lowest decimal value used in the calculation of -3. If there is a difference between the sum of the periods and the aggregate value reported the difference may be due to incorrect decimals associated with the individual fact values. The filer should check that the fact values do not have a decimal value that implies a higher level of accuracy than intended. In those rare cases where there are small immaterial differences that are less than 1% of the total and decimals are zero the rule can be overidden. This is performed by creating an extension element called ImmaterialDifferenceFlag. If this element has any value in any context in the instance then the immaterial difference will not result in an error. The rule excludes elements in the base taxonomy that cannot be aggregated such as an average, maximum or minimum value. The properties of this OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax fact are: Context: C_0be1f85e-14d7-44eb-9832-1198d86c8e1a, Unit: U_USD. srne-20230630.htm 1625, 1633, 2782 srne-20230630.htm srne-20230630.xsd srne-20230630_cal.xml srne-20230630_def.xml srne-20230630_lab.xml srne-20230630_pre.xml srne-ex31_1.htm srne-ex31_2.htm srne-ex32_1.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true